Dbv technologies announces filing of 2024 half-year report ― conditions for accessing or consulting the report

ChÂtillon, france, july 30, 2024 dbv technologies announces filing of 2024 half-year report ― conditions for accessing or consulting the report dbv technologies (euronext: dbv – isin: fr0010417345 – nasdaq stock market: dbvt), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “company”), today announced the filing, for the semester ended june 30, 2024, of its half-year report with the french market authority, “autoritÉ des marchÉs financiers” (“amf”). the 2024 half-year report can be consulted or downloaded from the company's website (www.dbv-technologies.com) in the section investors/financial information, and on the amf website (www.amf-france.org), in french only.
DBVT Ratings Summary
DBVT Quant Ranking